Interleukin-2 Phase 2 (NCT06096090) — Immunomodulation for AD

Executive Summary

flowchart TD
    Interleukin_2_Phase_2__NCT0609["Interleukin-2 Phase 2 (NCT06096090) — Immunomodu"] -->|"references"| FOXP3["FOXP3"]
    Interleukin_2_Phase_2__NCT0609["Interleukin-2 Phase 2 (NCT06096090) — Immunomodu"] -->|"references"| TREM2["TREM2"]
    style Interleukin_2_Phase_2__NCT0609 fill:#4fc3f7,stroke:#333,color:#000

This Phase 2 clinical trial investigates the use of low-dose interleukin-2 (IL-2) immunotherapy in patients with mild to moderate Alzheimer’s disease. The study, conducted at Houston Methodist Research Institute under the direction of Dr. Alireza Faridar, represents a novel approach to treating Alzheimer’s disease by targeting the immune dysregulation that contributes to neuroinflammation and disease progression.

Unlike conventional approaches that target amyloid or tau pathology directly, this trial focuses on modulating the immune system by expanding and restoring functional regulatory T cells (Tregs). This immunomodulation strategy addresses a critical but underappreciated component of Alzheimer’s disease pathophysiology.

Trial Overview

Scientific Rationale

Immune Dysregulation in Alzheimer’s Disease

Alzheimer’s disease is increasingly recognized as a disease with significant immune system dysfunction. Research over the past two decades has revealed that the immune system plays a dual role in Alzheimer’s disease:

1. Protective functions: Microglial cells clear amyloid, respond to pathogens, and maintain brain homeostasis

2. Pathogenic contributions: Chronic inflammation, impaired immune regulation, and autoimmune-like responses drive neurodegeneration

Key Immune Abnormalities in AD

Regulatory T Cells: The Immune “Brakes”

Regulatory T cells (Tregs) are a specialized subset of T cells that maintain immune homeostasis and prevent excessive inflammatory responses. They function as the “brakes” of the immune system, suppressing the activity of effector T cells, microglia, and other immune cells.

Treg Biology

1. Development: Tregs develop in the thymus (tTregs) or peripheral tissues (pTregs)

2. Surface markers: CD4+, CD25+, FOXP3+ (key transcription factor)

3. Mechanisms of suppression:

   • Cell-contact dependent inhibition

   • Cytokine secretion (IL-10, TGF-β, IL-35)

   • Metabolic disruption of effector cells

   • IL-2 consumption (competitive IL-2 deprivation)

Tregs in Alzheimer’s Disease

In Alzheimer’s disease, Tregs are compromised:

• Reduced numbers: AD patients show decreased circulating Tregs compared to age-matched controls

• Impaired function: Tregs from AD patients have reduced suppressive capacity

• FOXP3 dysregulation: Altered FOXP3 expression and methylation patterns

• Pro-inflammatory shift: Some Tregs convert to pro-inflammatory Th17 cells

This loss of immune regulation contributes to the chronic neuroinflammation that drives disease progression.

IL-2: The Treg Growth Factor

Interleukin-2 (IL-2) is a critical cytokine for Treg survival, proliferation, and function. Discovered in 1976, IL-2 was originally characterized as a T cell growth factor but is now understood to have complex, context-dependent effects on the immune system.

IL-2 Signaling

1. Receptor binding: IL-2 binds to the IL-2 receptor (CD25/CD122/CD132 trimeric complex)

2. Signal transduction: JAK-STAT, PI3K-AKT, and MAPK pathways

3. Cellular outcomes:

   • T effector cells: Proliferation, activation

   • Tregs: Survival, expansion, enhanced suppressive function

   • NK cells: Enhanced cytotoxicity

The Low-Dose IL-2 Paradox

A fascinating phenomenon in immunology is that low-dose IL-2 preferentially expands Tregs relative to effector T cells. This occurs because:

• Tregs constitutively express high levels of CD25 (IL-2 receptor alpha chain)

• This gives Tregs a competitive advantage for IL-2 binding at low concentrations

• Effector T cells require higher IL-2 concentrations for activation

• The result: selective Treg expansion with minimal effector cell activation

This selective effect makes low-dose IL-2 an attractive therapeutic strategy for diseases where Treg deficiency plays a role, including Alzheimer’s disease.

Study Design

Trial Type

This is a randomized, double-blind, placebo-controlled trial - the gold standard for clinical research.

Randomization

• Ratio: 1:1 (active:placebo)

• Stratification: By disease severity (MMSE score)

• Block size: Variable (4-6)

Treatment Arms

The study investigates two different dosing schedules to optimize the Treg expansion effect:

• Every 2 weeks: More frequent but lower total exposure

• Every 4 weeks: Less frequent with potential for higher individual doses

Dosing Rationale

The specific dose range is based on:

• Previous studies in other autoimmune conditions showing Treg selectivity

• Phase 1 safety data in elderly populations

• Target blood levels for optimal Treg expansion

• Balance between efficacy and safety

Eligibility Criteria

Inclusion Requirements

Exclusion Criteria

Key Assessments

Screening Evaluations

• Medical and neurological history

• Physical examination

• Cognitive testing (MMSE, CDR, ADAS-Cog)

• Laboratory tests (CBC, CMP, coagulation)

• Amyloid PET or CSF biomarkers

• MRI brain (within 6 months)

• ECG

• Lumbar puncture (for biomarker collection)

Treatment Period Evaluations

• Vital signs and physical exams at each visit

• Laboratory monitoring at regular intervals

• Cognitive testing at baseline, 3 months, 6 months

• CSF sampling at baseline and 6 months

• Adverse event monitoring

Endpoints

Primary Outcomes

Safety and Tolerability (6 months)

Safety assessments include:

• Adverse events (AEs) - incidence, severity, relationship

• Serious adverse events (SAEs) - monitoring for significant complications

• Laboratory abnormalities - hematology, chemistry

• Vital sign changes - blood pressure, heart rate, temperature

• ECG changes - cardiac safety monitoring

The primary safety concern with IL-2 is capillary leak syndrome (vascular leak syndrome), characterized by:

• Hypotension

• Edema

• Weight gain

• Reduced organ perfusion

Low-dose IL-2 minimizes this risk while maintaining Treg expansion.

Treg Percentage Change

Key immunologic endpoint:

• Measurement: Percentage of Tregs (CD4+CD25+FOXP3+) out of total CD4+ T cells

• Timepoints: Baseline, 2 weeks, 6 weeks, 3 months, 6 months

• Hypothesis: Low-dose IL-2 will increase Treg percentage by ≥50% from baseline

Secondary Outcomes

Exploratory Endpoints

• Treg functional assays (suppression capacity)

• Microbiome analysis (gut-immune-brain axis)

• Genetic predictors of response (IL2RA polymorphisms)

• Machine learning models for response prediction

Immunologic Monitoring

Treg Assessment Flow

Baseline → Week 2 → Week 6 → Month 3 → Month 6
   ↓          ↓         ↓          ↓          ↓
 Blood draws for flow cytometry analysis
   ↓
  ↓
Measure: CD4+CD25+FOXP3+ percentage and absolute count
         Treg suppressive function
         Serum IL-2 and soluble IL-2R

Biomarker Rationale

Mechanism of Action

How Low-Dose IL-2 May Benefit Alzheimer’s Disease

1. Treg Expansion

   • IL-2 stimulates proliferation of existing Tregs

   • Increases CD25 expression (positive feedback)

   • Promotes Treg survival and longevity

2. Immune Balance Restoration

   • Tregs suppress effector T cells and microglia

   • Reduces pro-inflammatory cytokine production

   • Shifts microglial phenotype from M1 (pro-inflammatory) to M2 (protective)

3. Neuroinflammation Reduction

   • Decreased IL-1β, TNF-α, IL-6 in the brain

   • Reduced microglial activation

   • Decreased T cell infiltration into CNS

4. Potential Disease Modification

   • By reducing chronic inflammation, may slow neurodegenerative processes

   • May preserve synaptic function and neuronal survival

   • May improve cognitive outcomes

Preclinical Evidence

Animal Models

• 5xFAD mice: Low-dose IL-2 reduced microglial activation and improved cognition

• APP/PS1 mice: IL-2 treatment decreased amyloid plaques via Treg-mediated mechanisms

• Aging mice: IL-2 restored Treg numbers and improved hippocampal function

Human Studies

• Autoimmune conditions: Low-dose IL-2 safely expands Tregs in SLE, RA, type 1 diabetes

• Cancer patients: High-dose IL-2 used for melanoma and renal cell carcinoma (different safety profile)

• Healthy elderly: IL-2 improves Treg function and immune parameters

Clinical Significance

Addressing an Unmet Need

Current Alzheimer’s disease treatments:

• Amyloid-targeting antibodies (lecanemab, donanemab): Important but only modestly effective

• Symptomatic medications (donepezil, memantine): Limited benefit

• Immunomodulatory approaches: Underdeveloped

This trial represents a different mechanism - targeting immune dysregulation rather than amyloid or tau directly.

Advantages of the Approach

1. Disease mechanism targeting: Addresses neuroinflammation, a core pathological feature

2. Combination potential: Could be combined with anti-amyloid therapies

3. Well-characterized safety: IL-2 has been used for decades in other conditions

4. Orphan mechanism: Targets the Treg deficiency in AD

5. Biomarker-driven: Can measure target engagement directly

Challenges and Limitations

1. CNS penetration: IL-2 is a large molecule; CNS effects may be indirect

2. Treg specificity: Some effector T cell activation may occur

3. Dosing optimization: Optimal dose and schedule not established for AD

4. Biomarker validation: CSF vs. blood Tregs correlation unclear

5. Long-term effects: 6-month treatment may be insufficient

Comparison with Other Immunotherapy Approaches

This trial is unique in targeting immune regulation rather than protein aggregation.

Regulatory Considerations

Current Status

• IND: Active

• Orphan drug: Not specifically for AD (immunomodulators have precedent)

• Fast track: Not granted (not a high-priority pathway)

Future Directions

If successful, this trial could:

1. Establish proof-of-concept for Treg-targeted therapy in AD

2. Identify biomarkers predicting response

3. Guide combination trials with anti-amyloid agents

4. Support expanded Phase 3 development

Patient Perspective

Burden of Alzheimer’s Disease

Alzheimer’s disease affects over 6 million Americans:

• Cognitive decline: Memory loss, disorientation, language difficulties

• Functional impairment: Loss of independence, need for caregiving

• Behavioral changes: Depression, agitation, sleep disturbances

• Family impact: Caregiver burden, financial costs, emotional distress

Current Treatment Limitations

• Symptomatic therapies: Provide modest, temporary benefit

• Disease-modifying therapies: Limited efficacy, significant risks (ARIA)

• Immunotherapy gap: No immunomodulatory approaches available

Potential Benefits of This Approach

If low-dose IL-2 is effective:

• Reduced neuroinflammation

• Slowed cognitive decline

• Maintained independence longer

• Improved quality of life

• Potential for combination with other therapies

Risks

• Flu-like symptoms (common with IL-2)

• Capillary leak syndrome (rare at low dose)

• Injection site reactions

• Potential for infection (immunosuppression)

• Unknown long-term effects

Future Directions

Next-Generation Immunomodulation

This trial represents the beginning of immune-targeted approaches:

1. Combination trials: IL-2 + anti-amyloid antibodies

2. Novel IL-2 formulations: PEGylated IL-2 for improved PK

3. Alternative targets: TREM2 agonists, CD22 inhibitors

4. Cell therapy: Ex vivo expanded Tregs

5. Microbiome modulation: Gut-immune-brain axis approaches

Biomarker Development

The trial incorporates extensive biomarker collection to:

• Validate target engagement (Tregs in blood/CSF)

• Identify predictors of response

• Enable patient selection for Phase 3

• Support regulatory approval

Related Pages

Disease and Mechanism Pages

• Alzheimer’s Disease — Overview of AD pathology and treatments

• Neuroinflammation — Mechanism of neuroinflammation in neurodegeneration

• Tau Protein — Target of other immunotherapies

• Amyloid Beta — Amyloid hypothesis and therapies

Therapeutic Approaches

• Immunotherapy Approaches for AD — Overview of immunotherapy strategies

• Anti-Amyloid Immunotherapy — Monoclonal antibody approaches

Related Clinical Trials

• Lecanemab (NCT01767311) — Anti-amyloid antibody

• Donanemab (NCT04468657) — Anti-amyloid antibody

• Tilavonemab (NCT03580956) — Anti-tau antibody